

INDEX

- 3-aminobenzamide, inhibition of
poly(ADP-ribos)ylation by, 122
- 3T3 cells, cell cycle delay after serum
refeeding, 77-78
- 5-fluorodeoxyuridine, induction of
prostatic apoptosis by, 148
- Acute leukemia, genetic abnormalities in,
210
- ADCC, independence of antibody-induced
apoptosis from, 241
- ALS, penetrance in families of, 11-12
- Amiloride, effect on apoptosis of, 261
- Androgen ablation, prostatic genes
expression changes induced by,
141-142
- Antiproliferative drugs, interactions with
cell cycle control mechanisms of,
227-230
- Aphidicolin
apoptosis in HeLa cells induced by, 229
multipolar mitosis in HeLa cells induced
by, 229-230
temporal patterns of apoptosis induced
by, 227-230, 232-233
- APO-1 cell surface antigen
apoptosis induced by antibody reacting
with, 237, 239
apoptosis mediation by, 237-240
bone marrow purging by antibody
against, 247
expression in different tissues of, 238,
241, 244
human gene of, 238
identity with the Fas antigen of, 238,
241, 243
inflammation-associated induction of,
238
lpr gene defect due to a defect in, 216
molecular structure of, 238
presence on activated and malignant
human lymphocytes of, 237
- APO-1 Cell surface antigen (*cont'd*)
purification and molecular cloning of,
237-238
relationships to TNF of, 245
role in activation induced apoptosis in T
and B cells, 239
role in the thymus of, 243
search for a ligand of, 246-247
toxicity in primates of antibody against,
247-248
upregulation by interferon and TNF of,
244
- Apoptosis, *see* also programmed cell
death (PCD)
32D cells density and induction of, 88
activation by intracellular Ca²⁺ signals
of, 98-105
bcl-2 independent suppression of, 242
cell cycle dependence of, 114, 228
cyclins levels during induction of, 234-
235
dependence on duration of cell cycle
arrest of, 224-227, 231-232
endonucleases associated with, 249-264
enforced MYC expression overrides
growth factors induced suppression
of, 86
genetic mechanisms of regulation of, 80
IGF-I-mediated protection from, 70
imbalanced cell cycle progression and,
234-235
independence from cell cycle phase, 231
independence from nuclease-mediated
DNA cleavage, 100
induction of
by anti-mitotic drugs, 224-227
by C2 ceramide, 245
by cell-cycle phase specific drugs,
223-236
by *c-myc*, 86, 88, 256
by conflicting growth signals, 52

Apoptosis (*cont'd*)

- by E1A *myc* chimeras, 95
- by IL3 withdrawal, 35
- by inhibitors of DNA synthesis, 227-230, 232
- by nuclear oncogenic events, 256
- by wt p53 activity, 32
- in APO-1 negative cells transfected with APO-1, 243-244
- inhibition of
 - by IGFs, 68-71
 - by insulin, 68-69
- intracellular pH and, 255-257
- ion signalling and activation of, 97-117
- lack of DNA fragmentation in, 166
- lymphocytes clones deletion by, 211
- mechanism of regulation of, 53
- molecular mechanisms of induction of, 82-83
- morphological criteria for, 249
- multiple pathways of regulation of, 53
- p53 independent types of, 62
- phases in the development of, 97-98
- phosphorylation of membrane ion transporters in protection from, 256
- possible effects on cell cycle progression of, 235-236
- priming by *myc* expression for, 88
- protective effects of TPA, 263-264
- regulation by adenovirus transforming gene products of, 47-61
- regulation in interleukin-3-dependent myeloid progenitor cells, 85-96
- role of
 - in immune tolerance, 218-219
 - in negative selection of thymic cells, 179-181
 - in nuclear oncogenic events, 256
 - in pathological states, 97
 - in regulation of hematopoiesis, 85
- role of Ca²⁺/Mg²⁺-dependent endonucleases in, 99-100, 249-251
- role of Ca²⁺ signals in the activation of, 98-105
- simultaneous death of sister cells in, 82
- suppression by hemopoietic growth factors of, 85-88, 90-91
- survival factors influences on, 134
- temporal dependence on protein synthesis of, 235

- Apoptotic bodies, formation in thymocytes of, 102-104
- Arrestin, expression in *rds* mice of, 19
- Ataxia-telangiectasia, phenotypic characteristics of, 122
- Ataxia-telangiectasia cells
 - cell cycle checkpoint defect in, 122
 - defective induction of p53 protein following irradiation of, 122
- Ataxia-telangiectasia gene, increased tumor risk determined by defects in, 123-125
- Aurintricarboxylic acid, inhibition of apoptosis by, 250
- Basic fibroblast growth factor, *see* bFGF
- bcl-2*
 - apoptosis and functional expression of, 161-163, 169, 171-174, 232
 - cell cycle arrest signals and function in apoptosis of, 163
 - cell death blocked by, 161-162, 171
 - cellular function of, 158-164
 - chromosomal location of, 157-158
 - delay of apoptosis induced by, 174
 - effects on B lymphocytes survival, 84, 158-163
 - expression in retina of, 168
 - function in non-lymphoid tissues of, 161
 - functional redundancy of, 168-169
 - functional similarities with *raf*, 91
 - half-life of, 170
 - homology with *mcl-1* of, 161, 169
 - influence on differentiation of, 171
 - inhibition of induction of apoptosis by, 47, 49, 53, 72-73, 92, 196-197
 - intracellular localization and function of, 162-163, 167-170
 - knockouts of, 168
 - localization in pancreas of, 167-168
 - regulation of apoptosis by, 53, 157-174
 - regulation of cell survival by, 158-159
 - role in thymic development of, 160-161
 - suppression of p53-induced apoptosis by, 47-48, 51, 53
 - TNF cytotoxicity after inhibition of apoptosis by, 59-60
 - transgenic mice with overexpression of, 84, 158-159, 166
 - turnover of protein encoded by, 172

- bFGF, 68
 apoptosis of hepatocytes induced by, 23
 effects on retinal degeneration of, 22
- C₂-ceramide, mediation of TNF-induced toxicity by, 115
- Ca²⁺
 effects on chromatin conformation, 110
 flux in nuclei, 109-110
 induction of apoptosis in G₀ cells, 145-146
 role of
 in the activation of apoptosis, 98-105
 in gene expression, 105, 110
- Ca²⁺-binding protein, prevention of glucocorticoids-induced apoptosis by, 99
- Ca²⁺-dependent endonucleases
 role in apoptosis of, 100
 cellular expression of, 114
- Caffeine, potentiation of DNA damaging agents by, 119-122
- Calcium ionophore, prevention of apoptosis by, 112
- Camptothecin
 cell cycle phase dependence of DNA breaks by, 170
 DNA repair after treatment with, 162-163
- Castration
 intracellular changes induced by, 140-141
 role of proliferation in prostatic cell death induced by, 142
- ced* genes, expression of, 6, 10-11
- ced-9*
 functional similarity to bcl-2 of, 3
 similarities to MCL-1 of, 7
- C. elegans*, 1-13
 asymmetric cell division and cell death in, 7-8
 genetic pathways of programmed cell death in, 2-13
 pathway for signal transduction in, 1-2
 processes involved in aging of, 11
- Cell cycle progression
 checkpoints during, 117-119, 123-176, 231
 dependence of apoptosis on pathways of, 225-227
- Cell cycle progression (*cont'd*)
 DNA damage and control of, 117-135
 function of p53 status after ionizing irradiation, 120-122
 p53 and A-T gene products in the control of, 117-135
 regulation by IFN related transcription factors of, 208-209
 role of calmodulin and Ca²⁺ in the regulation of, 105
- Cellular pH, regulation of, 255
- ces-1*, structure of, 10-11
- c-fos*
 diurnal variation in retinas, 19
 induction of apoptosis by, 52-53
- Chromatin organization, role in transcription and apoptosis of, 101-102, 110, 113
- Cisplatin
 activation of deoxyribonuclease II by, 256
 DNA cross-links produced by, 251-252
 induction of apoptosis by, 227-230, 232, 256-257
 multipolar mitoses induced by, 262-263
- c-myc*
 apoptosis-inducing activity of mutants of, 66-67
 cell proliferation and apoptosis induced by, 83
 dual signal model for apoptosis induced by, 71
 effect of ODC inhibitors on apoptosis induced by, 94
 functional dimerization partners of, 92-93
 functions of nuclear phosphoprotein encoded by, 64
 growth-promoting function of, 64-66
 immediate early response gene function of, 63, 85
 induction by
 of apoptosis, 52-53, 65-71, 86
 of IL-3, 85, 90
 of mechanisms of apoptosis, 86, 91-92, 256
 of models for apoptosis, 67-71, 213-214
 of ODC, 88-90

c-myc (cont'd)

- mitogen induced expression of, 85
 - modulation of, 63-65, 85-89, 216-218, 220, 223-224,
 - oncogene and tumor suppressor gene function of, 63-85
 - oncogenic synergy with bcl 2, 72
 - overexpression in colonic tumors, 79-80
 - overriding cell cycle regulation by, 78-79, 86
 - promotion by EGF of apoptosis induced by, 83
 - protection by cytokines of apoptosis induced by, 68-69
 - role in
 - colon carcinogenesis, 79-80
 - late phase of the cell cycle, 211
 - radiation induced T-cell apoptosis, 223
 - T-cells activation-induced apoptosis, 216-218
 - role of wt p53 in apoptosis induced by, 77
 - separation of apoptosis from transformation induced by, 95-96
 - sequence specific DNA binding of, 64, 66-67, 85
 - suppression of apoptosis by, 86
 - synergism with *raf*, 90
 - transcription activation by, 85-86, 89
- ### Colcemid
- induced by
 - aberrant mitotic events, 263
 - apoptosis, 224-227, 231-232
 - multipolar mitosis, 225-227
- ### Cyclic-GMP phosphodiesterase, mutations in *rd* mice of, 15, 23, 27
- ### Cycloheximide
- apoptosis induction by, 69-70, 242
 - blockage of G₁ arrest after ionizing irradiation by, 121
- ### Cyclosporin A
- blockage of T cell activation-induced apoptosis by, 214
 - induction of auto-immune syndrome by, 222
 - inhibition of thymocyte apoptosis by, 179
- ### Cytokines
- modulation of cycloheximide-induced apoptosis by, 70

Cytokines (*cont'd*)

- transcription factors as targets of, 199
- ### Cytolytic T-cells, novel mechanisms of killing by, 174-175
- ### Diabetes, retinopathies associated with, 28
- ### DNA
- intracellular acidification consequent to fragmentation of, 252-253, 259-260
 - repair in prostatic cells following castration, 142-143
- ### DNA damage, molecular events controlling cellular responses to, 99-100, 117-126, 261-262
- ### E1A proteins
- apoptosis induced in a p53-less cell by, 60
 - binding by Rb of, 48-49
 - binding to cyclin A of, 49
 - DNA synthesis induced by, 48
 - induction of apoptosis by, 47-49
 - interference with cell cycle control by, 49
 - mediation by wt p53 of apoptosis induced by, 49-52
- ### E1B proteins
- binding of p53 by, 47
 - inhibition of apoptosis by, 47-49, 51, 53, 58-59
 - prevention of p53-dependent apoptosis by, 47, 49, 53, 58-59
- ### EBV, *c-myc* activation in B cells infected by, 81
- ### Endonuclease(s)
- activation of, 249-263
 - apoptotic DNA digestion by, 252-254
- ### Ca²⁺/Mg²⁺-dependent type of, 249-251
- effect of depletion of intracellular Ca²⁺ on, 260-261
 - pH dependent activation of, 263
- ### Engulfment genes
- expression of, 9, 12
 - genetic pathway for, 2-3
 - site of action of, 10
- ### Etoposide, 12, 83
- apoptosis induced by, 70, 252-253
 - pH changes in cells exposed to, 253-254
- ### Fas, anti-viral immune surveillance by, 48

GADD45 gene, 129
induction dependence on normal p53 function, 129
protein encoded by, 130
transcription in irradiated A-T cells, 122-123

Glucocorticoids
apoptosis of thymocytes induced by, 180, 250
role in thymocyte selection, 186

Growth factor, signal transduction pathways mediated by, 255-256

H1 histone, possible role in apoptosis of, 115

HeLa cells
apoptosis induced by aphidicolin in, 227-232
complementation of Bcl-2 for the E1B 19K protein, 51-52
stringent mitotic checkpoint control in, 224-227
wt p53 dependent induction of apoptosis in, 50-51

Hemopoietins, suppression of PCD by, 86

Hydroperoxycyclophosphamide, cell cycle phase dependence of DNA breaks induced by, 170

IGF-1, Insulin-like growth factor 1
apoptosis suppression by, 82
induction of immediate early growth response transcription factors by, 69
receptors expression in fibroblasts, 74-75
regulation of cell growth by, 199-210

IL3, interleukin 3
inhibition of p53 induced apoptosis by, 34-35

IL3-dependent mouse myeloid cell line, (32D), 35-38, 85-96
apoptosis with increasing density of, 88
biosynthetically labeled p53 from, 35-36
effects of *raf* on apoptosis in, 90
effects of survival factors on death of, 37-38
expression of p53 in sublines of, 43
IL-3-independent growth promoted by *v-myc* plus *v-raf* in, 91
inappropriate cycling of *myc* clones of, 86-88
kinetics of death in the absence of IL3, 36-37

IL6, interleukin 6
effects on the cell cycle of p53-expressing M1 cells, 45
inhibition of wt p53 induced apoptosis by, 33-35
pleiotropic effects on M1 cells, 34-35

Inherited retina degeneration, *rds* mouse model of, 17-21
apoptosis inhibition by growth factors and cytokines in, 23, 29

Insulin, 68

Interferon, anti-proliferative effects of, 201

Intracellular pH, regulation of, 255

Intranuclear pH, changes during apoptosis of, 113-114

Ion transport, regulation across the nuclear envelope of, 101

Ionizing radiation
cell cycle arrests induced by, 119
cell cycle checkpoints activated by, 124
changes in p53 protein consequent to, 120

Ionomycin, cells acidification induced by, 252

IRF-1, Interferon regulatory factor 1
DNA binding domains of, 201
growth of cells with the human form of, 204-206
induction of, 201, 205-207, 212
levels in nonproliferating tissues, 208-209
negative regulation of cell growth by, 206
reversion of transformed cells by, 204-206

IRF-1/IRF-2 ratio, oscillation during cell cycle of, 202, 206

IRF-2, Interferon regulatory factor 2
DNA binding domains of, 201
growth properties of cell lines with overexpression of, 202-204
regulation of, 201, 209
regulation of cell growth by, 201-212

IRFs, transcriptional regulation by, 201

Liver cells nuclei, effects of Ca²⁺ and pH changes in, 101-102

lpr, defect of Fas/APO-1 expression in mice with the phenotype of, 239-241, 243, 246

lpr syndrome, possible determinants of, 239

- Mad overexpression, growth arrest of fibroblasts induced by, 77
- Max overexpression, growth arrest in fibroblasts induced by, 77
- MC-29, tumor induction by, 78,80-81
- MCF7 cells, apoptosis induced by anti-APO-1 in, 246
- mcl-1*, 161, 169
homology to *bcl-2*, 161
- mdm2 protein, binding to p53 protein of, 123
- Methylglyoxal-bis(guanylhydrazone), mitochondrial effects of, 95-96
- Methylprednisolone, apoptosis induced by, 102-104
- Metyrapone, effects on apoptosis, 186
- Myelodysplastic syndrome, p53 status in, 213-214
- Myeloid cells, sequential gene activation in transformation of, 92
- Nematode *Caenorhabditis elegans*, *see C. elegans*, 1-13
- Nitrogen mustard, DNA repair after treatment with, 162-163
- NK-cells, novel mechanisms of killing by, 174-175
- nuc-1*, role in PCD of, 4-6
- ODC, Ornithine decarboxylase
causal relationship between apoptosis and regulation of, 96
premature apoptosis consequent to constitutive expression of, 90
requirement for cell progression of, 88
- p34^{cdc2} kinase, regulation of entry into mitosis by, 256
- P450^{scc}, thymic expression of, 181, 186
- p53
adenovirus transformation after mutation of, 60-61
anti-proliferative capacity of, 32
binding by E1B of, 47
binding site in *GADD45* for, 122-123
cell cycle checkpoints dependence on, 119-126
dependence of ionizing radiation-induced apoptosis on, 125-126
hematopoietic survival factors and activity of, 31-45
- P53 (*cont'd*)
effect(s) of
PALA on induction of, 131
ras on function of, 61-62
effects on decision point in late G1, 32, 33
expression in IL3 dependent cells, 35
functional blockage by mdm2 of, 123
genetic instability associated with loss of function of, 125-126, 131
increased tumor risk determined by defects in, 123-125
induction of apoptosis by, 32, 256
inhibition of
apoptosis dependent on, 33-35, 51
cell proliferation by, 134
mediation of E1A-induced apoptosis by, 47-48
point mutations in, 31
post-transcriptional increases after ionizing radiation, 120-121
relationship to cell cycle progression of apoptosis mediated by, 32
response elements of, 31
role in
c-myc-induced apoptosis, 77
determining apoptosis of, 39, 44
determining G₁ arrest following ionizing radiation, 119-122
E1A-induced apoptosis, 49-51
the cellular response to DNA damage, 119-121
sequence-specific transcription factor role, 31
signal transduction induced by, 122-123
A-T, *GADD45* and *MDM2* genes involvement in, 122-123
stability upon IL3 withdrawal, 42
temperature sensitive mutant of, *see p53 Val135*
tumor suppressor properties of, 31
type of DNA damage triggering the induction of, 131
- p53 heterozygotes, differences in the response to radiation of, 130
- p53 mutants, IL3 dependent proliferation of, 42
- p53 Val135, induction of apoptosis in M1 cells by, 32

- PCD, Programmed cell death, *see also*
 Apoptosis
 genetic control of, 1-13
 regulation by *bcl-2* of, 157-174
 role of *nuc-1* gene in, 5-6
 sequential changes in non-proliferating
 prostatic glandular cells during,
 139-141
 therapeutic implication for prostatic
 cancer of, 145-146
- PDGF, 68
 apoptosis suppression by, 82
- Peripherin
 alterations in the gene for, 18
 structure of, 27
- Phagocytosis, activation in retinopathies
 of, 28
- PKC, role in apoptosis of, 114
- Polyamines
 depletion of pools, 95
 prevention of apoptosis by, 101, 104,
 105, 111-113
- Pregnenolone, synthesis in the thymus of,
 183-185
- Prostate
 activation of Ca^{2+} - Mg^{2+} -dependent
 endonucleases during apoptosis in,
 140-141
 measurement of apoptotic index in, 154
 redefinition of the "cell cycle" in, 143-
 145
 role of cell proliferation in the induction
 of apoptosis by castration in, 142
 sequence of events in glandular cells
 PCD induced by androgen ablation
 in, 138-142
 trophic interactions and apoptosis in,
 153-154
- Prostate cancer
 proliferation independent activation of
 PCD as a novel therapy for, 137-155
 role of tumor cells heterogeneity in
 progression of, 137
- RAD9, yeast DNA-damage responsive
 cell cycle checkpoint, 117-119
- raf*
 dependence of *ras* induced fibroblast
 transformation on, 90
 functional similarities with *bcl-2*, 91
 induction of immediate early gene
 promoters by, 90
- raf (cont'd)*
 suppression of *myc* associated apoptosis
 by, 92
 synergism with *myc*, 90-91
- Rb
 binding to
 E1A, 49
 transcription factor E2F, 49
 late G1 mechanisms of action, 49
- RCS rat
 apoptotic photoreceptor cell death in
 retinas of, 17-24
 retinal pathology in, 16, 21-33
- rds* mice
 apoptotic changes in retina of, 16-24
 electron micrographs of retinas at
 various ages in, 19-20
 endonucleases action in retina of, 20-21
 factors affecting survival of retinas in, 27
 survival of photoreceptors in, 18-19
- rds/peripherin* gene, mutations in mice
 and humans, 15, 23, 27
- Retina
 inherited degenerations of, 15-19
 normal development of, 16-17
- Retinoic acid
 effects on
 T cell hybridoma, 187-188
 T-cell viability independent of TCR
 interactions, 196
 inhibition of activation-induced
 thymocyte PCD, 184, 189, 191
 pleiotropic effects, 199
 receptors for, 184
 role in thymocyte development, 187,
 189-190 Rhodopsin gene, mutations
 of, 15, 23, 27
- SOD protein, involvement in cell death, 8-
 10
- Spermine, prevention of glucocorticoid-
 induced apoptosis in thymocytes by,
 93-94
- Staurosporin, apoptosis-like process
 initiated in enucleated cells by, 110
- Steroid(s)
 differential sensitivity of T-cells to, 196
 ontogeny of thymic synthesis of, 183-184
 sensitivity of TCR-negative cells to,
 196-197
 thymic expression of receptor for, 194-
 195

- Steroidogenesis, thymic enzymes for, 181
- Superoxide dismutase, protection from
TNF induced toxicity by, 115
- T cells
- activation-induced apoptosis and
negative selection of, 212
 - antagonism between AP-1 and steroid
receptors in, 195
 - apoptosis-independent negative
selection of, 214
 - Fas/Apo-1, apoptosis and peripheral
deletion of, 216-218
- T cell receptor, thymocyte selection and
avidity of, 180
- TGF β , inhibition of *c-myc* expression by,
216
- Thapsigargin, TG
- ability to activate prostatic PCD, 146-
148
 - apoptotic changes induced by, 147-148
 - chemical structure, 146
 - effects of *bcl-2* and p53 on apoptosis
induced by, 151
 - effects on intracellular Ca²⁺, 100, 146-
147
 - epigenetic reprogramming of cells
induced by, 148
 - prevention of thymic apoptosis by, 111-
113
 - therapeutic modification of, 148-149,
152-153
- Thymic nurse cells
- characteristics of, 183
 - role in thymocyte development of, 188
- Thymocytes
- activation-induced apoptosis in, 214
 - apoptosis induced by Ca²⁺ ionophores
in, 250
 - effect(s) of
dexamethasone on subpopulations of,
195-196
- Thymocytes (*cont'd*)
- steroids on selection of, 180-181
 - negative selection of potentially
autoreactive T cells in, 179
 - nuclear receptors and apoptosis in, 179-
199
 - ontogeny of steroid synthesis in, 182-
183
 - P450scc expression in, 181-186
 - phenotype in vitamin A-deficient mice,
190
 - positive selection of antigen-specific
effector T cells in, 179
 - sensitivity to glucocorticoid-induced
PCD, 180
 - staphylococcal enterotoxin B induced
deletion in *lpr/lpr* mice of, 216-218
 - steroidogenic enzymes in, 181-182
 - synthesis of pregnenolone in, 183-184
 - TCR/glucocorticoid antagonism model
for selection of, 181, 190-191
- T internal antigen, TIA
- apoptosis induced by, 175-176
 - restriction to cytolytic T-cells, 174-175
 - RNA binding by, 175
- Transcription factors, regulation of cell
growth by, 201-212
- Tumor necrosis factor, TNF- α
- anti-viral immune surveillance by, 48
 - apoptosis in human adenocarcinoma
cells treated with, 104
 - endonuclease activation and apoptosis
by, 99
 - induction of *c-myc* and *c-fos* expression
by, 53
 - inhibition by E1B 19K of apoptosis
induced by, 48,51
 - p53-independent cytotoxicity, 60
 - relationships to APO-1, 245
- Verapamil, prevention of DNA
fragmentation and apoptosis by, 9